These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 19039322)

  • 21. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
    Gamas P; Marchetti S; Puissant A; Grosso S; Jacquel A; Colosetti P; Pasquet JM; Mahon FX; Cassuto JP; Auberger P
    Leukemia; 2009 Aug; 23(8):1500-6. PubMed ID: 19340007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
    Rix U; Remsing Rix LL; Terker AS; Fernbach NV; Hantschel O; Planyavsky M; Breitwieser FP; Herrmann H; Colinge J; Bennett KL; Augustin M; Till JH; Heinrich MC; Valent P; Superti-Furga G
    Leukemia; 2010 Jan; 24(1):44-50. PubMed ID: 19890374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
    Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
    Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
    Hill BG; Kota VK; Khoury HJ
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
    Redaelli S; Boschelli F; Perini P; Pirola A; Viltadi M; Gambacorti-Passerini C
    Leukemia; 2010 Jun; 24(6):1223-7. PubMed ID: 20445575
    [No Abstract]   [Full Text] [Related]  

  • 30. Bosutinib treatment for Philadelphia chromosome-positive leukemias.
    Bethelmie-Bryan B; Lord K; Holloway S; Khoury HJ
    Future Oncol; 2014 Feb; 10(2):179-85. PubMed ID: 24490604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
    Wermuth PJ; Jimenez SA
    PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
    Isfort S; Crysandt M; Gezer D; Koschmieder S; Brümmendorf TH; Wolf D
    Recent Results Cancer Res; 2018; 212():87-108. PubMed ID: 30069626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1
    Gleixner KV; Sadovnik I; Schneeweiss M; Eisenwort G; Byrgazov K; Stefanzl G; Berger D; Herrmann H; Hadzijusufovic E; Lion T; Valent P
    Leuk Res; 2019 Mar; 78():36-44. PubMed ID: 30711891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
    Konig H; Holyoake TL; Bhatia R
    Blood; 2008 Feb; 111(4):2329-38. PubMed ID: 18056843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
    Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.
    Yuan X; Zhang Y; Zhang H; Jin J; Li X; Liu H; Feng Z; Chen X
    Leuk Res; 2011 Feb; 35(2):237-42. PubMed ID: 20739063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.